Skip to Content

Join the 'Taxotere' group to help and get support from people like you.

Taxotere News

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Isotretinoin, Rituxan, Claravis

Keytruda May Help Fight Tough-to-Treat Lung Cancer

Posted 21 Dec 2015 by Drugs.com

SATURDAY, Dec. 19, 2015 – The immune therapy drug Keytruda (pembrolizumab) may extend the lives of people with advanced lung cancer, a new study finds. Keytruda is commonly used to treat other tumor types, and made headlines recently after it helped former President Jimmy Carter fight off brain cancer. In this study, researchers compared Keytruda to the chemotherapy drug docetaxel in more than 1,000 patients with non-small cell lung cancer. All of the patients were battling tumors that had progressed even after chemotherapy. Non-small cell lung cancer is the leading form of the disease. All of the patients' tumors produced a protein called PD-L1, which can shield the tumor from immune system attack, according to a team led by Dr. Roy Herbst, professor of medicine at Yale University School of Medicine. Among patients with the highest amounts of PD-L1, those who received Keytruda lived ... Read more

Related support groups: Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Taxotere, Keytruda, Docetaxel, Docefrez

New Drug May Boost Survival a Bit for Some With Advanced Lung Cancer

Posted 28 Sep 2015 by Drugs.com

SUNDAY, Sept. 27, 2015 – A new study finds that the cancer drug nivolumab (Opdivo) extends the lives of some patients with advanced lung cancer for several months. In a head-to-head comparison, patients treated with nivolumab lived an average of 12.2 months, while patients treated with the chemotherapy drug docetaxel lived an average of 9.4 months, the researchers reported. "It looks like we have a new treatment option for patients with metastatic lung cancer that progresses after standard chemotherapy," said lead researcher Dr. Hossein Borghaei, chief of thoracic medical oncology at Fox Chase Cancer Center in Philadelphia. "Now we have another tool, but we have to learn how to make it better so people can even live longer," he said. The results of this phase 3 trial, which was funded by nivolumab's maker Bristol-Myers Squibb, were to be presented Sunday at the European Cancer Congress ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Taxotere, Opdivo, Docetaxel, Nivolumab, Docefrez, Bronchogenic Carcinoma

Immune-Based Drug Shows Potential Against Another Form of Lung Cancer

Posted 1 Jun 2015 by Drugs.com

SUNDAY, May 31, 2015 – Another study finds that a new immune system-focused drug, called nivolumab, may help treat a common form of lung cancer. On Saturday, a study presented at the annual meeting of the American Society of Clinical Oncology in Chicago found that nivolumab cut patients' risk of death from non-small cell lung cancer (NSCLC) – the most common form of the disease – by 27 percent, compared with patients who received an older drug called docetaxel. Now, a second study to be presented Sunday at the meeting finds nivolumab also boosted one-year survival for patients with a subset of NSCLC, called squamous cell NSCLC. That study is being published simultaneously in the New England Journal of Medicine. Forty-two percent of people with squamous cell NSCLC who got nivolumab were still alive one year later, compared to 24 percent of those who got docetaxel, according to a team ... Read more

Related support groups: Lung Cancer, Taxotere, Opdivo, Docetaxel, Nivolumab, Docefrez

Immune-Based Drug Shows Promise Against Advanced Lung Cancer

Posted 29 May 2015 by Drugs.com

FRIDAY, May 29, 2015 – A new drug appears to harness a person's immune system to fight the most common form of lung cancer, according to new clinical trial findings. The drug, nivolumab, reduced patients' risk of death from non-small cell lung cancer by 27 percent compared with patients who received docetaxel, a commonly used chemotherapy medication, researchers said. The study results are scheduled for presentation Saturday at the annual meeting of the American Society of Clinical Oncology, in Chicago. Nivolumab – marketed as Opdivo – primarily helps patients whose tumor cells carry a trait that allows their cancer to avoid detection by the immune system. As a result, overall median survival was 12.2 months in the nivolumab group compared to 9.4 months in the docetaxel group, the researchers reported. Also, only one in 10 patients experienced serious side effects with nivolumab, ... Read more

Related support groups: Lung Cancer, Non-Small Cell Lung Cancer, Taxotere, Opdivo, Docetaxel, Nivolumab, Docefrez

Early Chemo May Boost Survival in Advanced Prostate Cancer

Posted 14 May 2015 by Drugs.com

THURSDAY, May 14, 2015 – Starting the chemotherapy drug docetaxel at the same time as hormone therapy can improve survival for men with newly diagnosed, advanced prostate cancer, British researchers say. Currently, chemotherapy is generally given after hormone therapy stops working. But the new study found that when the two therapies were paired at the start of treatment, patients lived an average of 10 months longer. The combination had even greater benefits for men whose prostate cancer had spread to other parts of their bodies – known as "metastatic" cancer. These men experienced an average 22-month improvement in their overall survival, the findings showed. "We hope our findings will encourage doctors to offer docetaxel to men newly diagnosed with metastatic prostate cancer, if they are healthy enough for chemotherapy," said lead author Dr. Nicholas James, director of the Cancer ... Read more

Related support groups: Lupron, Prostate Cancer, Lupron Depot, Reclast, Zoladex, Zometa, Zytiga, Aclasta, Taxotere, Eligard, Lupron Depot 3.75 mg, Zoledronic Acid, Xtandi, Leuprolide, Degarelix, Lupron Depot-PED, Supprelin, Firmagon, Trelstar, Docetaxel

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Cephalexin, Clindamycin, Penicillin, Methotrexate, Azithromycin, Bactrim, Cipro, Ciprofloxacin, Accutane, Augmentin, Levaquin, Lupron, Flagyl, Keflex, Zithromax

New Guidelines for Treating Advanced Prostate Cancer

Posted 8 Sep 2014 by Drugs.com

MONDAY, Sept. 8, 2014 – Men newly diagnosed with prostate cancer often turn first to testosterone-depleting therapies, since male hormones help prostate tumors grow. But, those therapies almost always fail over time as the tumor develops resistance, according to oncologists. Now, experts are issuing updated guidelines to help patients in this situation decide what to do next. The guidelines, issued jointly by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) in Canada, highlight recent advances in treating this more advanced form of prostate cancer. "We have seen unprecedented progress against advanced prostate cancer recently, with six new treatments approved in the last couple of years," Dr. Ethan Basch, co-chair of the ASCO/CCO panel of experts that developed the guidelines, said in a news release from the two groups. "There are a lot of nuances about ... Read more

Related support groups: Prostate Cancer, Ketoconazole, Zytiga, Nizoral, Casodex, Taxotere, Xtandi, Bicalutamide, Provenge, Docetaxel, Abiraterone, Xofigo, Flutamide, Radium 223 Dichloride, Jevtana, Sipuleucel-t, Cabazitaxel, Nilandron, Docefrez, Mitoxantrone

FDA Medwatch Alert: Docetaxel: Drug Safety Communication - May Cause Symptoms of Alcohol Intoxication

Posted 24 Jun 2014 by Drugs.com

ISSUE: FDA is warning that the intravenous chemotherapy drug docetaxel contains ethanol, also known as alcohol, which may cause patients to experience intoxication or feel drunk during and after treatment. FDA is revising the labels of all docetaxel drug products to warn about this risk.  BACKGROUND: Docetaxel is a prescription chemotherapy drug used to treat different kinds of cancer, including cancers of the breast, prostate, stomach, head and neck cancers, and non-small-cell lung cancer.  RECOMMENDATION: Health care professionals should consider the alcohol content of docetaxel when prescribing or administering the drug to patients, particularly in those whom alcohol intake should be avoided or minimized and when using it in conjunction with other medications. Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these p ... Read more

Related support groups: Cancer, Taxotere, Docetaxel, Docefrez

New Approach May Boost Survival From Advanced Prostate Cancer

Posted 2 Jun 2014 by Drugs.com

SUNDAY, June 1, 2014 – Adding the chemotherapy drug docetaxel to standard hormone-depleting therapy may extend the lives of men with advanced prostate cancer, a new study finds. The study was to be presented Sunday in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO). "Hormone therapy has been a standard treatment for prostate cancer since the 1950s," lead author Christopher Sweeney, a medical oncologist at the Dana-Farber Cancer Institute in Boston, explained in an ASCO news release. "This is the first study to identify a strategy that prolongs survival in newly diagnosed metastatic prostate cancer," he added. "The benefit is substantial and warrants this being a new standard treatment for men who have [extensive] disease and are fit for chemotherapy." One expert not connected to the new trial agreed. "These data are practice-changing and help us ... Read more

Related support groups: Prostate Cancer, Taxotere, Docetaxel, Docefrez

New Treatment for Aggressive Breast Cancer Shows Some Promise

Posted 11 Dec 2013 by Drugs.com

WEDNESDAY, Dec. 11, 2013 – Women with aggressive breast cancer who receive combination targeted therapy with chemotherapy prior to surgery have a slightly improved chance of staying cancer-free, researchers say. However, the improvement was not statistically significant and the jury is still out on combination treatment, said lead researcher Dr. Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels. "I don't think that tomorrow we should switch to a new standard of care," she said. Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other research that investigated ways to improve treatment for women with HER2-positive breast cancer. This aggressive form of cancer is linked to a genetic irregularity. Other researchers reported the following: The targeted drug trastuzumab (Herceptin) worked better in ... Read more

Related support groups: Breast Cancer, Herceptin, Taxotere, Carboplatin, Docetaxel, Tykerb, Trastuzumab, Lapatinib, Carboplatin Novaplus, Paraplatin, Docefrez

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Rituxan, Isotretinoin, Claravis, Votrient, Anastrozole, Tarceva

Drug Combo Might Fight Aggressive Breast Cancer More Safely

Posted 5 Oct 2011 by Drugs.com

WEDNESDAY, Oct. 5 – Treating women with an aggressive form of early stage breast cancer using Herceptin and chemotherapy, while not turning to a third type of drug known as an anthracycline, improves survival while posing less danger to the heart, researchers report. They tested three different regimens, one of which did not include any anthracyclines. When Herceptin is given with doxorubicin (Adriamycin), an anthracycline, toxic cardiac effects have been seen. "What the study shows is you have comparable effectiveness in a Herceptin-based regimen when you don't use the anthracyclines," said Dr. Dennis Slamon, director of clinical and translational research at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles. Earlier research of his led to the development of Herceptin (trastuzumab). He contends that the new regimen should be the new standard of care, ... Read more

Related support groups: Breast Cancer, Herceptin, Taxotere, Carboplatin, Adriamycin, Doxorubicin, Docetaxel, Adriamycin RDF, Docefrez, Adriamycin PFS, Carboplatin Novaplus, Paraplatin

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Renal Cell Carcinoma, Rituxan

Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph

Posted 4 Dec 2010 by Drugs.com

WEDNESDAY, Dec. 1 – A chemotherapy regimen already proven superior to other regimens for breast cancer that has spread to the lymph nodes may also work better for some women whose cancers haven't spread, a new study has found. When it came to these "node-negative" cancers, the drug combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said. The TAC regimen was better at keeping women alive and disease-free after a median follow up of almost six and a half years, the study found. ''For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said study co-author Dr. Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid. ... Read more

Related support groups: Breast Cancer, Taxotere, Docetaxel

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Breast Cancer, Metastatic, Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer, Solid Tumors

Taxotere Patient Information at Drugs.com